[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Einecke
Dirk
D
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood*; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology*; D004359:Drug Therapy, Combination; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008137:Longitudinal Studies; D010919:Placebos; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010919:Placebos; D011743:Pyrimidines; D011758:Pyrroles; D011804:Quinolines; D013449:Sulfonamides; C483909:torcetrapib; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D017035:Pravastatin